Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) and Reliv’ International (OTCMKTS:RELV – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.
Institutional and Insider Ownership
35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 7.7% of Reliv’ International shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by insiders. Comparatively, 30.0% of Reliv’ International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Zevra Therapeutics and Reliv’ International, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zevra Therapeutics | 0 | 2 | 9 | 0 | 2.82 |
| Reliv’ International | 0 | 0 | 0 | 0 | 0.00 |
Risk & Volatility
Zevra Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Reliv’ International has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500.
Earnings and Valuation
This table compares Zevra Therapeutics and Reliv’ International”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zevra Therapeutics | $106.47 million | 6.32 | $83.23 million | $0.92 | 12.33 |
| Reliv’ International | $35.06 million | 0.09 | -$440,000.00 | ($0.09) | -20.33 |
Zevra Therapeutics has higher revenue and earnings than Reliv’ International. Reliv’ International is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Zevra Therapeutics and Reliv’ International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zevra Therapeutics | 42.82% | 54.54% | 34.15% |
| Reliv’ International | -0.61% | -1.89% | -1.31% |
Summary
Zevra Therapeutics beats Reliv’ International on 13 of the 14 factors compared between the two stocks.
About Zevra Therapeutics
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
About Reliv’ International
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
